8000 Marina Boulevard
About Aimmune Therapeutics
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for life-threatening food allergies. Our mission is to improve the lives of people with food allergies by developing and commercializing proprietary desensitization therapies that safely and reliably protect them from accidental exposure to food allergens. Aimmune’s first investigational product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients.
133 articles with Aimmune Therapeutics
Aimmune Reports Positive Findings For ARC002 Follow-On Phase II Study Of AR101 For Treatment Of Peanut Allergy
Aimmune Receives European Medicines Agency Decision Agreeing With PIP For AR101 For The Treatment Of Peanut Allergy
Aimmune Announces Closing Of Initial Public Offering And Full Exercise Of Underwriters' Option To Purchase Additional Shares